Background: Chronic kidney disease (CKD) is associated with cardiac hypertrophy that leads to increased cardiovascular morbidity and mortality. To date, use of the renineangiotensinealdosterone system blockade has been the main treatment modality. However, renineangiotensinealdosterone system blockade by the angiotensin converting enzyme inhibitors (ACEi) can only partially reverse the cardiac hypertrophy without having a significant impact on all-cause mortality as evidenced by meta-analyses from clinical trials. It is imperative to elucidate the molecular pathogenesis of CKD-related cardiomyopathy for potential targets in further treatment. Methods: Male SpragueeDawley rats that underwent subtotal nephrectomy (SNX) rats were established as the CKD model. A hemodynamic study was used to evaluate the left ventricle (LV) structural and functional alterations. We used proteomic techniques to profile the LV protein changes among sham-operated rats, SNX rats, and SNX rats with 6 months of ACEi enalapril interventions. The differentially expressed proteins were further annotated by functional and network analyses. Results: As compared to the sham-operated rats, the SNX rats had 25 upregulated and 46 decreased protein expression. The top canonical pathways identified by ingenuity pathway analysis for the CKD cardiomyopathy were mitochondrial dysfunction, oxidative phosphorylation, fatty acid b oxidation, protein ubiquitination, and ketolysis. The most relevant functions extracted from these networks contained 27 and 23 focused proteins, respectively. They were related to cellular assembly and organization, RNA posttranscriptional modification, and protein synthesis. After ACEi intervention for 6 weeks, the residual canonical pathways identified by ingenuity pathway analysis that mediated the CKD-related cardiomyopathy were mitochondrial dysfunction, ketolysis, phenylalanine degradation IV, and putrescine degradation III. There were decreased Sirt3 and SNRNP, and increased monoamine oxidase and SAHH expression in the LV of SNX rats that could not be reversed by the ACEi. Conclusion: Our studies provide a repertoire of potential biomarkers related to cardiac hypertrophy in CKD. There are still residual disturbed molecules/pathways despite ACEi intervention. Further studies are warranted to investigate these potential novel targets to alleviate CKD-related cardiomyopathy.
Introduction
The prevalence of chronic kidney disease (CKD) is expanding rapidly worldwide. Although enormous efforts have been devoted to alleviate renal function deterioration, cardiovascular disease remains the main cause of morbidity and mortality in this population.
Contrary to the multitude of randomized control trials (RCTs) for cardiovascular diseases in the general population, there are still limited studies specifically designed for CKDrelated cardiac dysfunctions. 1 RCTs for cardiovascular diseases often exclude renal impairment patients at the very beginning of enrollment. Nevertheless, for the few RCTs of renal diseases that have been reported, they seldom considered cardiovascular parameters as the composite end point for analysis. 2 Therefore, current treatment strategies toward CKD-related cardiovascular disease have mainly been derived from experience with nonrenal dysfunction patients. It should be noted that besides the traditional cardiovascular risk factors, there are specific uremia-related milieus that contributed to the cardiovascular pathology. Without a comprehensive understanding of the molecular signatures and pathways, it would be impossible to develop specific therapeutic interventions for this CKD-related cardiac dysfunction.
Because CKD is well known for the uncontrolled activation of renineangiotensinealdosterone system (RAAS), RAAS blockade [e.g., ACE inhibitors (ACEi) by enalapril] has been the mainstay cardiovascular treatment modality. 3 However, a recent Cochrane review of four RCTs that enrolled 2177 stage 1e3 nondiabetic CKD patients suggested that ACEi had no impact on all-cause mortality. 4 For those CKD 5 patients under maintenance hemodialysis, the secondary analysis of the RCT of HEMO (originally targeted toward dialysis dose and membrane flux) also revealed that ACEi could not significantly affect mortality or cardiovascular morbidity, 5 and even unexpectedly had a higher risk of heart failure hospitalization. When taking left ventricular mass (LVM) as the surrogate marker, Dyadyk et al 6 reported that ACEi (captopril and enalapril) could only induce regression in 12e19% of LVM in hypertensive CKD patients. Our previous 12-month RCT with the ACEi ramipril also failed to render significant regression of LVM in normotensive hemodialysis patients. 7 Therefore, it is imperative to elucidate mechanisms beyond RAAS that mediate the pathogenesis of uremic cardiomyopathy.
Proteomic techniques have been adopted to investigate cardiovascular biology. 8 However, there is still scarce application of these techniques to study CKD-related cardiomyopathy. In this study, we used advanced proteomic techniques to unravel the molecular signatures of uremic-related cardiomyopathy, and to search for the remaining pathological pathway/molecules after RAAS blockade by ACEi treatment. We endeavored to improve our incomplete understanding of the pathophysiology of CKD-related cardiomyopathy and explore the potential candidate targets for therapeutic interventions.
Methods

Rat subtotal nephrectomy model
This study was conducted according to the guidelines of the Taipei Veterans General Hospital Committee on Animal Care and Supply, Taipei, Taiwan. Male SpragueeDawley rats (from National Laboratory Animal Center, Taipei, Taiwan) (200e250 g) were housed in animal care facilities with living conditions maintained as follows: 12-hour light/dark cycles, temperature at 21 C, and humidity at 70%. The rats were randomly allocated into three groups: sham-operated (SO), subtotal nephrectomy (SNX) with vehicle (corn oil), and SNX with the ACEi enalapril (3 mg/kg/d). The rat SNX models were established similar to that in previous studies by removing one kidney and two-thirds of the remaining kidney at two stages. 9 The SO group received two-stage bilateral renal decapsulation. After the surgical procedures were completed, the rats were gavaged with either vehicle or enalapril for 6 weeks. All rats were provided standard food (containing 40 g protein and 0.6 g NaCl per 100 g) and tap water ad libitum.
Hemodynamic study
The rats were anesthetized with intraperitoneal pentobarbital sodium (40 mg/kg body weight). During the procedure, the rat's body temperature was maintained at 37 C with a small animal blanket. The neck was carefully dissected to isolate the right carotid artery, through which a 1.9F conductance catheter (Scisense FT212, Ontario, Canada) was introduced into the ascending aorta. The systolic and diastolic blood pressures of the rats were then recorded to represent the central blood pressure.
Subsequently, the conductance catheter was advanced into the left ventricle (LV) to obtain the left ventricle hemodynamic parameters. The heart rate, LV end-systolic pressure, LV enddiastolic pressure, LV end-systolic volume, and LV enddiastolic volume were recorded. The systolic function are indexed by ejection fraction, peak positive value of the time derivative of LV pressure (dP/dt min ), and cardiac output, which is derived from (stroke volume) Â (heart rate). The diastolic function parameters are represented by the peak negative value of the time derivative of LV pressure (dP/dt min ) and isovolumetric relaxation constant (microseconds).
Preparation of crude tissue extracts
After the hemodynamic study, the rats were sacrificed via an intraperitoneal injection of superdose sodium pentobarbital. Each heart was harvested, perfused with phosphate-buffered saline, and weighed, after which the left ventricles were further dissected. For each rat, 100 mg of the left ventricle was minced and treated with 500 mL of extraction buffer [0.5 M Tris, pH 6.8, 0.1% sodium dodecyl sulfate (SDS)] containing the complete protease inhibitor cocktail (Roche, Mannheim, Germany) and PhosSTOP phosphatase inhibitor cocktail (Roche). Then, each sample was homogenized individually and centrifuged at 20,630g for 30 minutes at 4 C (Model 5922; Kubota Corp., Tokyo, Japan) to remove cell debris. The supernatants were collected, and total protein concentrations were determined using the protein assay rapid kit (Wako Pure Chemical Industries, Osaka, Japan).
SDS-polyacrylamide gel electrophoresis and in-gel digestion
Rat left ventricular protein samples were fractionated by 10% SDS-polyacrylamide gel electrophoresis, similar to a previously described method. 10 The gels were stained with CBB staining solution (0.1% CCBG-250, 34% methanol, 17% ammonium sulfate, and 3% O-phosphoric acid), and 50 mg of each protein sample was loaded onto the gel in triplicate. The gel lanes were cut into 10 fractions based on molecular weight, and the gel slices were destained repeatedly in a solution of 25 mM NH 4 HCO 3 and 50% (v/v) acetonitrile (1:1). After drying in a Speed-Vac (concentrator 5301; Eppendorf AG, Hamburg, Germany), the slices were incubated with 1% b-mercaptoethanol and 25 mM NH 4 HCO 3 for 20 minutes at room temperature. For cysteine alkylation, an equal volume of 5% 4-vinylpyridine in 25 mM NH 4 HCO 3 and 50% acetonitrile was added for 20 minutes. After soaking the slices in 1 mL 25 mM NH 4 HCO 3 for 10 minutes, the slices were dried in a Speed-Vac for 20 minutes. Then, 200 ng of modified trypsin (Promega, Mannheim, Germany) in 25 mM NH 4 HCO 3 was added, and tryptic digestion was performed at 37 C overnight. The tryptic digest was removed from the gel, dried in a Speed-Vac, and stored at À20 C until further analysis. The tryptic peptides were resuspended in 20 mL 0.1% (v/v) formic acid immediately before use.
Mass spectrometric analysis
Tryptic peptide samples were injected into a nanoflow HPLC system (Agilent Technologies 1200 series; Agilent Technologies, Waldbronn, Germany) coupled to an LTQ- Table 1 Characteristics and hemodynamic data of the sham-operated, subtotal nephrectomy þ vehicle, and subtotal nephrectomy þ enalapril rats. Data are expressed as mean ± standard error. *p < 0.05 compared to sham-operated rats. **p < 0.05 compared to subtotal nephrectomy þ vehicle rats. dP/dt max ¼ maximum derivative of change in systolic pressure over time; dP/dt min ¼ maximum derivative of change in diastolic pressure over time. Orbitrap Discovery hybrid mass spectrometer with a nanoelectrospray ionization source (Thermo Electron, Waltham, MA, USA). The tryptic peptides were separated on an Agilent C18 column (100 mm Â 0.075 mm, particle size 3.5 mm).
Mobile-phase solvent A was prepared as 0.1% formic acid in water, and solvent B as 0.1% formic acid in acetonitrile. The peptides were eluted from the column with a linear gradient of 5e35% solution B for 90 minutes and 35e95% solution B for 10 minutes. The eluted peptides were ionized with a spray voltage of 2 kV and then introduced into the mass spectrometer (MS). MS data were obtained using the data-dependent acquisition method (isolation width: 1.5 Da), in which one full MS survey scan (m/z ¼ 200e2000) at a high resolution of 30,000 at full-width half maximum was followed by a tandem mass spectrometry (MS/MS) scan of the six most intense ions with 2 þ and 3 þ charge states. Fragment ions of each selected precursors were generated by collision-induced dissociation using helium gas with collision energy of 35 eV.
Database searching
The LC-MS/MS raw data were analyzed using the Xcalibur 2.0.7 SR1 software (Thermo Electron), processed by an inhouse server where the peptide sequences were identified against the Universal Protein Resource Knowledgebase, a rat protein database (UniProt; http://www.uniprot.org/) that contains ion scans obtained from MS/MS data. The lists of searching parameters were set as follows: peptide mass tolerance of 1.0 Da; fragment ion tolerance of 1.5 Da, enzyme designated as trypsin; one missed cleavage by trypsin was allowed; oxidation on methionine (þ16 Da) was allowed as variable modifications. Positive protein identification was based on the following criteria for an assigned peptide as Xcorr !2.2 for 2 þ , and 3.75 for 3 þ charged ions. A protein was considered to be identified when at least two peptides were matched with the above Xcorr scores. MS spectral counts were normalized on the sum of the spectral counts per biological sample for quantitative analyses.
Pathway analysis
The differentially expressed left ventricular proteins between SO and SNX þ vehicle, and those between SNX þ vehicle and SNX þ enalapril were uploaded with their corresponding Swiss-Prot accession numbers into the ingenuity pathway analysis (Ingenuity Systems, www.ingenuity. com) for networks and functional analyses.
Western blotting
Frozen left ventricle tissues were pulverized into a fine powder under liquid nitrogen, dissolved in a lysis buffer (9.5 M urea, 2% w/v CHAPS. 0.8% w/v Pharmalyte, pH 3e10 and 1% w/v DTT) containing protease inhibitors, and then centrifuged at 20,630g for 10 minutes. The supernatant were collected and the protein concentration determined by use of the Bradford method (Bio-Rad, Hercules, California, USA). Samples with equal protein amounts were fractionated on 10% SDS-polyacrylamide gel electrophoresis, then transferred to polyvinylidene difluoride membranes. After the membrane was blocked with the blocking solution (5% skim milk), it was incubated with the primary antibodies as SirtT3 (Cell Signaling), SNRNP200 (Abnova), Monoamine Oxidase A and SAHH (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 C overnight. The membrane was subsequently incubated with peroxidase-conjugated secondary antibody. After washing, the blots were visualized using the enhanced chemiluminescence method, and ImageJ software was used to quantify the image signal.
Statistical analysis
Data are expressed as mean ± SE. All statistical analyses were conducted using SPSS, version 19.0 (SPSS Inc., Chicago, IL, USA). Unpaired Student t test was conducted for comparisons between groups, and analysis of variance was used for comparisons among groups. A p value <0.05 was considered statistically significant.
Results
Biochemical and hemodynamic data
Blood and urine measurements for each SO, SNX þ vehicle, and SNX þ ACEi rat were performed every 2 weeks to ensure a successful establishment of the animal model and monitor treatment effects. As demonstrated in Table 1 , the SNX rats had significantly more impaired renal function indexed by increased blood urea nitrogen and creatinine than the SO rats. However, 6 weeks of enalapril treatment could partially improve the renal function. The SNX rats had markedly higher carotid systolic and diastolic blood pressure, and enalapril could lower the blood pressure. The SNX fed with vehicle had a significant hypertrophic heart as indicated by the increased heart weight/body weight ratio. Those SNX rats treated with enalapril demonstrated less cardiac hypertrophy. Fig. 1 illustrates the representative left ventricle blood pressure signals acquired from control rats, SNX rats treated with vehicle, and SNX rats treated with ACEi. Compared to SO controls, SNX rats had significantly higher left ventricular systolic pressure, which could be lowered by enalapril treatment.
Cardiac structural and functional alteration
SNX rats demonstrated a similar heart rate and systolic function (indexed by dP/dt max , ejection fraction, and cardiac output) when compared with sham controls (Table 1) . However, there was impaired diastolic function as shown by the decreased dP/dt min and increased isovolumetric relaxation time. Compared with SNX rats receiving vehicle dosing, AECi treatment tended to improve diastolic function.
Comparative proteomics and pathway analysis
Compared to SO rats, SNX rats had 25 upregulated and 46 decreased protein expressions in the left ventricle. The top canonical pathways that participated in CKD cardiomyopathy were mitochondrial dysfunction, oxidative phosphorylation, fatty acid b oxidation, protein ubiquitination, and ketolysis (Fig. 2) . From a total of nine overlapping networks generated by ingenuity pathway analysis (Ingenuity Systems; www. ingenuity.com), six had a score >10 (score !2 is significant; it represents the log of the probability that the network was found by chance) ( Table 2 ). The most relevant functions extracted from these networks contained 27 and 23 focused proteins, respectively (Fig. 3) . They were related to cellular assembly and organization, RNA posttranscriptional modification, and protein synthesis (Table 2) .
Compared to SO rats, SNX rats treated with enalapril for with 6 weeks had 21 upregulated and 40 decreased protein expressions in the left ventricle. The residual canonical pathways mediating the CKD-related cardiomyopathy were mitochondrial dysfunction, ketolysis, phenylalanine degradation IV, and putrescine degradation III (Fig. 4) . The most relevant functions extracted from the top two networks contained 24 and 15 focused proteins, respectively (Fig. 5 ). They were related to cellular assembly and organization, free radical scavenging, and renal damage (Table 3 ). Compared to SO rats for the most differentially expressed left ventricular proteins, there was a markedly decreased sirt3 and SNRNP200, and increased monoamine oxidase (MAO) and adenosylhomocysteinase (AHCY) for SNX rats treated with enalapril.
Western blot analysis
Expressions of Sirt3, SNRNP, MAO, and SAHH of the left ventricles from SO, SNX þ vehicle, and SNX þ enalapril rats were further validated by Western blot analysis (Fig. 6) . Concordant with the proteomic findings, there was decreased expression of Sirt3 and SNRNP. However, there was also increased MAO and SAHH expression in renal dysfunctional status, which could not be ameliorated by enalapril.
Discussion
In the present study, we used the CKD model of SNX rats to investigate the alterations of left ventricular structure function in renal impairment status, and to evaluate the therapeutic effects of RAAS blockade by ACEi. We observed preserved systolic function and impaired diastolic function in SNX, which resembles the heart failure with preserved ejection fraction 11 found in CKD patients. ACEi cannot fully reverse the LV structural and functional derangements in CKD. Proteomic analysis of the SNX left ventricle revealed deranged functional pathways related to mitochondrial dysfunction, fatty acid b oxidation, protein ubiquitination, RNA posttranscriptional modification, and ketolysis. Again, ACEi could not thoroughly correct these irregularities. We observed markedly decreased sirt3 and SNRNP200, and increased MAO and AHCY in the left ventricles of enalapriltreated SNX rats, which could be promising candidates for multiple-target therapy.
SIRT3
We observed decreased Sirt3 and NAMPT in the SNX heart, which could not be reversed by ACEi. Sirtuins are class III histones that necessitate nicotinamide adenine dinucleotide (NAD) for their activity with deacetylases. Sirt3 governs the substrate for myocardial energy utilization by activating enzymes implemented in tricarboxylic acid cycle, fatty acid b oxidation, and ketogenesis. Therefore, Sirt3 played a pivotal role in cardiac hypertrophy, a state that the substrate for myocardial energy utilization switches from fatty acid b oxidation to glycolysis. Sirt3 also exerts cardioprotective effects by activating the Foxo3a-dependent antioxidant defense mechanism that scavenges cellular reactive oxygen species (ROS) and prevents cardiac hypertrophy. 12 NAMPT is a stress and nutrient-responsive protein that participates in the biosynthesis of NAD, which is responsible for the activity of sirtuins. Exogenous NAD has been shown to activate AMPactivated protein kinase, to rescue the heart from ATP depletion, stimulate PGC1a, and block the cardiac hypertrophic response. 13 We speculate that identifying drugs or nutrients (e.g., NAD supplementations) capable of increasing Sirt3 expression or activity might be an attractive strategy to ameliorate CKD-related cardiomyopathy. 14 
SNRNP200
In the SNX LV, we observed decreased expression of SNRNP200 helicase and PRPF8, which are the major components of spliceosome. The spliceosome is composed of five small nuclear ribonucleoproteins and hundreds of proteins. It plays a crucial role in alternative splicing of premessenger RNAs by recognizing the intron/exon boundaries, catalyzing the removal of introns, and joining of exons. Through alternative splicing of the precursor transcripts, various mature mRNAs are produced and subsequently translated into functionally diverse protein isoforms from a single gene. Deranged exon exclusion, intron retention, or the use of alternative splice sites could significantly influence the protein structure, localization, regulation, and function. Disturbed expression of U5 small nuclear ribonucleoprotein associated U5-200kD RNA helicase could also cause cell cycle abnormalities. 15 Alternative splicing of sarcomeric genes, ion channels, and cell signaling proteins can lead to cardiomyopathies, arrhythmias, and other pathologies. 16 Based on the decreased expression of components in spliceosome, further studies are warranted to unravel the role of alternative splicing and RNA targets in the pathogenesis of CKD cardiomyopathy. 
MAO
MAOs are the flavoenzymes located at the outer membrane of mitochondria, which are the major sources of ROS in cardiomyocytes. 17 They are responsible for the oxidative deamination of catecholamines, serotonin, and biogenic amines. During the process of MAO-mediated deamination, the byproduct as aldehydes could be deleterious to the heart by deactivating proteasomes and altering mitochondrial bioenergetics. 18 Therefore, there are intricate connections among MAO activation, mitochondrial ROS formation, and mitochondrial dysfunction, 19 all of which are involved in myocardial degeneration in heart failure and aging. 20 Remarkably, several transcriptomic or proteomic studies have already identified upregulated MAO-A in experimental rat heart failure models of volume overload, 21 pressure overload, 22 and myocardial infarction, 23 and suppression of myocardial MAO has displayed beneficial effects. In vitro studies have shown that senescent cardiomyocytes exhibited distinctly enhanced MAO-A activity, and cardiomyocytes exposed to angiotensin II displayed marked MAO activation. 24 Given that CKD is a status of enhanced RAAS activation reflected by increased angiotensin II 25 and accelerated senescence, 26 and that CKD cardiomyopathy is the combination of pressure and volume overloads, 27 we think that MAO inhibition might be promising for alleviating cardiac pathologies.
AHCY
S-Adenosylhomocysteine hydrolase (AHCY) catalyzes the hydrolysis of S-adenosylhomocysteine to homocysteine and adenosine, 28 which is the only source of homocysteine in mammals. Increased AHCY expressions were detected in our study, particularly in the SNX left ventricles that denote the increased homocysteine generation in situ. Homocysteine could induce endothelial dysfunction through the decreased bioavailability of nitric oxide and increased oxidative stress on vasculature causing thrombosis liability. It could also injure cardiomyocytes through the activation of p38 MAPK, decreased expression of thioredoxin, and increased ROS production, ultimately leading to impaired cardiomyocyte contractility and apoptosis. 29 Hyperhomocysteinemia is the well-recognized risk factor for cardiovascular complications in CKD. 30 However, several RCTs aimed to decrease the blood homocysteine level failed to render improved clinical outcomes. We reasoned that lower blood homocysteine does not necessarily reflect the real tissue concentration in CKD left ventricles. It would be innovative to evaluate whether suppressing AHCY activity would be beneficial to cardiac hypertrophy.
Others
Several other potential proteins may merit further evaluation. The SNX rats had an increased expression of MURC (musclerestricted coiled-coil protein), a member of the caveolin family, 31 which is the hypertrophy-regulated gene that increases myocardial expression under pressure overload. 32 It modulates the rho/rock pathway, and induces cardiac dysfunction and conduction disturbance. There is decreased FHL2 in the SNX left ventricle in the present study. FHL2 functions to suppress calcineurin signaling and NFAT (nuclear factor of activated T cell) activation, and consequently inhibits pathological cardiac growth. 33 Actually, decreased FHL2 expression is also observed in failing human hearts. 34 Moreover, we also found decreased FABP3 (heart-type fatty acid binding protein-3), which is a cytosolic fatty acid shuttle that facilitates the movement of fatty acids in cardiac muscle. It reversibly binds and moves fatty acids from the plasma membrane into storage or to the mitochondria for oxidation. Decreased FABP3 expression might hamper cardiac fatty acid utilization and increase the dependence on glucose as a substrate.
In conclusion, consistent with previous clinical reports, we observed that simply using the RAAS blockade by ACEi could not untangle the intricate pathways involved in CKD-related cardiomyopathy in this animal study. Further comprehensive investigations of these pathways and the renocardiac network would facilitate the development of a multifaceted intervention for clinical applications in the future.
